Clinical investigator, CaMMouflage Phase 1 trial
Appears in 1 story
Presented CB-011 dose escalation data at Tandem 2026
Every approved cancer cell therapy on the market today requires the same costly bottleneck: extracting a patient's own immune cells, engineering them in a lab over weeks, and infusing them back — a process that costs over $400,000 and leaves some patients waiting so long their cancer outpaces the manufacturing. On March 31, 2026, the Food and Drug Administration (FDA) granted accelerated regulatory status to CB-011, the first donor-derived cell therapy engineered to hide from a patient's immune system, after it produced a 92% response rate in a Phase 1 trial for multiple myeloma — a blood cancer that kills roughly 12,000 Americans each year.
Updated 2 days ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
